Billy Amzal
Billy Amzal is Head of Strategic Consulting at Phastar.
Over the past 25 years, Billy has developed statistical methodologies to inform and support strategic decision-making in healthcare. Prior to joining Phastar, Billy led the model-based drug development team at Novartis. He then developed and led implementation of statistical methodologies for high-impact research sponsored by public and global health agencies (the European Food Safety Authority (EFSA), Global Fund and the US National Institutes of Health (NIH)). Billy has also been Senior Vice-President at Certara, where he was in charge of data and decision analytics, and Chief Executive Officer/Chief statistician at Quinten Health, an AI company pioneering digital twins and disease modelling.
Billy still acts as statistical expert for public health organisations (the European Medicines Agency (EMA), the World Health Organization (WHO) and the Gates Foundation).
He has led hundreds of trial design and analytics projects, authored more than 100 publications, defended/submitted 100 regulatory and reimbursements dossiers, and led hundreds of data modelling or machine learning projects.
JournalThe EU’s Health Technology Assessment Regulation: Implementation one year on
This article looks at the impact of EU-HTAR on national HTA bodies, developers and patients so far, and discusses what comes next